Tech Company Financing Transactions

Rapport Therapeutics Funding Round

Arch Venture Partners, Johnson & Johnson Innovation and Third Rock Ventures participated in a $100 million Series A venture round for Rapport Therapeutics. This VC investment round was announced on 3/7/2023.

Transaction Overview

Announced On
3/7/2023
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Series A
Investors

Arch Venture Partners (Lead Investor)

Johnson & Johnson Innovation (Lead Investor)

Third Rock Ventures (Lead Investor)

Proceeds Purpose
The company intends to use the funds to accelerate growth, expand operations and its business reach.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
201 Brookline Ave 1401
Boston, MA 02215
USA
Email Address
Overview
As a word, Rapport describes relationships characterized by understanding, communication, teamwork, and trust. We reflect those qualities in our daily work, where we operate as one committed team that captures the collective knowledge and experience of all our members to maximally improve patients' lives. And at a higher level we share an ambition and a passion to create impactful neuromedicines, with fewer side effects, that allow patients and their families to live healthier and more fulfilling lives. On a molecular scale, our deep understanding of the intricate relationships between receptors, their associated proteins, and their distributions in specific cell types and brain regions enables us to precisely direct medicines to the neural circuits underlying disease pathophysiology.
Profile
Rapport Therapeutics LinkedIn Company Profile
Social Media
Rapport Therapeutics Company Twitter Account
Company News
Rapport Therapeutics News
Facebook
Rapport Therapeutics on Facebook
YouTube
Rapport Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Abraham Ceesay
  Abraham Ceesay LinkedIn Profile  Abraham Ceesay Twitter Account  Abraham Ceesay News  Abraham Ceesay on Facebook
Chief Medical Officer
Brad Galer
  Brad Galer LinkedIn Profile  Brad Galer Twitter Account  Brad Galer News  Brad Galer on Facebook
Chief Scientific Officer
David Bredt
  David Bredt LinkedIn Profile  David Bredt Twitter Account  David Bredt News  David Bredt on Facebook


 

 

Browse more venture capital transactions:

Prev: 3/7/2023: Opkit venture capital transaction
Next: 3/7/2023: Plus One Robotics venture capital transaction

 

Share this article

 


About Our Venture Capital Transactions Database

We report on every notable VC transaction. VC investment data records on this site are derived from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary